Novo Nordisk stock was dropping on Wednesday after Roche said it had licensed a promising obesity drug in a deal that could ...

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...

Weight loss drugs like Ozempic deliver more health benefits than expected.

Roche and Zealand Pharma inked a $5.3 billion deal Wednesday to collaborate on a weight-loss drug in the amylin class.

From going blind and suffering from life-long diarrhea to battling addiction and finding love, people who take Ozempic and other GLP-1 medications are seeing that the drugs are doing more than ...

Ascletis' ASC47 shows 1.7% weight loss vs. placebo in Phase 1b trial, Vivace gets a $35M Series D for VT3989, and Harbour BioMed launches obesity startup Élancé Therapeutics.

Roche & Zealand join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. Find out why this ...

Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss pharmaceutical firm signed an exclusive agreement with Zealand Pharma to produce ...

Swiss pharmaceutical company Roche struck a multibillion-dollar collaboration and licensing deal with Zealand Pharma to co-develop a weight-loss treatment. Shares in Roche rallied in Europe, while ...

The makers of weight-loss drugs Wegovy and Zepbound are cutting prices to make the medications more affordable for people without insurance.

Social support can improve the odds of successful weight loss. AnnaLee Canario and Dacia Benjamin say their friendship is the secret to their success with GLP-1s.

Swiss drugmaker Roche on Wednesday announced a major deal in the weight-loss category, agreeing to pay up to $5.3 billion to Zealand Pharma in a licensing and development agreement. Zealand Pharma's ...